Hepcidin levels in diabetes mellitus and polycystic ovary syndrome

Diabetic Medicine

Volumn 30, Issue 12, 2013, Pages 1495-1499

  Sam, A H ^a   Busbridge, M ^b   Amin, A ^a   Webber, L ^a   White, D ^a   Franks, S ^a   Martin, N M ^a   Sleeth, M ^a   Ismail, N A ^a   Daud, N Mat ^a   Papamargaritis, D ^a   Le Roux, C W ^a   Chapman, R S ^b   Frost, G ^a   Bloom, S R ^a   Murphy, K G ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; GLUCOSE; HEPCIDIN;

ARTICLE; BLOOD SAMPLING; BODY MASS; CIRCADIAN RHYTHM; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FERRITINS; HEPCIDINS; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME;

EID: 84887588232     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12262     Document Type: Article

References (19)

1. Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB. The role of iron in type 2 diabetes in humans. Biochim Biophys Acta 2009; 1790: 671-681.
2. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002; 51: 2348-2354.
3. Tuomainen TP, Nyyssonen K, Salonen R, Tervahauta A, Korpela H, Lakka T et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1013 eastern Finnish men. Diabetes Care 1997; 20: 426-428.
4. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51: 1000-1004.
5. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810.
6. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-7819.
7. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
8. Piperno A, Girelli D, Nemeth E, Trombini P, Bozzini C, Poggiali E et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood 2007; 110: 4096-4100.
9. van Dijk BA, Laarakkers CM, Klaver SM, Jacobs EM, van Tits LJ, Janssen MC et al. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. Br J Haematol 2008; 142: 979-985.
10. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
11. Busbridge M, Griffiths C, Ashby D, Gale D, Jayantha A, Sanwaiya A et al. Development of a novel immunoassay for the iron regulatory peptide hepcidin. Br J Biomed Sci 2009; 66: 150-157.
12. Luque-Ramirez M, Alvarez-Blasco F, Alpanes M, Escobar-Morreale HF. Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96: 846-852.
13. Le Guenno G, Chanseaume E, Ruivard M, Morio B, Mazur A. Study of iron metabolism disturbances in an animal model of insulin resistance. Diabetes Res Clin Pract 2007; 77: 363-370.
14. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75: 976-981.
15. Tussing-Humphreys LM, Nemeth E, Fantuzzi G, Freels S, Guzman G, Holterman AX et al. Elevated systemic hepcidin and iron depletion in obese premenopausal females. Obesity (Silver Spring) 2010; 18: 1449-1456.
16. Jiang F, Sun ZZ, Tang YT, Xu C, Jiao XY. Hepcidin expression and iron parameters change in Type 2 diabetic patients. Diabetes Res Clin Pract 2011; 93: 43-48.
17. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-1044.
18. Martinelli N, Traglia M, Campostrini N, Biino G, Corbella M, Sala C et al. Increased serum hepcidin levels in subjects with the metabolic syndrome: a population study. PLoS One 2012; 7: e48250.
19. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535-582.